Zafgen, Inc. (ZFGN) Lowered to Hold at Zacks Investment Research
Zacks Investment Research lowered shares of Zafgen, Inc. (NASDAQ:ZFGN) from a buy rating to a hold rating in a research report report published on Friday.
According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, ValuEngine lowered shares of Zafgen from a sell rating to a strong sell rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $6.38.
Zafgen (ZFGN) traded down 2.03% during trading on Friday, reaching $3.37. 158,390 shares of the company traded hands. The firm’s 50 day moving average price is $3.45 and its 200 day moving average price is $3.98. Zafgen has a 12-month low of $2.89 and a 12-month high of $5.46. The firm’s market capitalization is $92.62 million.
Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter in the prior year, the business posted ($0.55) earnings per share. Equities research analysts expect that Zafgen will post ($2.23) earnings per share for the current year.
In related news, insider Dennis D. Kim bought 10,000 shares of the company’s stock in a transaction dated Tuesday, July 11th. The stock was purchased at an average cost of $3.39 per share, with a total value of $33,900.00. Following the transaction, the insider now owns 21,443 shares in the company, valued at approximately $72,691.77. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 21.20% of the company’s stock.
Large investors have recently bought and sold shares of the company. Algert Global LLC purchased a new stake in shares of Zafgen in the 2nd quarter worth about $123,000. Parametric Portfolio Associates LLC lifted its position in shares of Zafgen by 55.8% in the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 10,327 shares during the period. Wells Fargo & Company MN lifted its position in shares of Zafgen by 1,290.3% in the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 40,400 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Zafgen in the 2nd quarter worth about $259,000. Finally, LMR Partners LLP purchased a new stake in shares of Zafgen in the 2nd quarter worth about $299,000. 48.52% of the stock is owned by hedge funds and other institutional investors.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.